Navigation Links
The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
Date:5/21/2008

SHANGHAI, China, May 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has acquired a QPatch HT automated patch clamp system, the first unit introduced into China by Sophion Bioscience.

The drug discovery process in pharmaceutical companies begins with identifying potential targets for new diseases. One important class of targets is ion channels that regulate the flow of ions across cellular membranes and therefore influence the physiology of all cells. Patch clamp is a widely applied gold-standard technique for the study of ion channels. Speed and accuracy of automated patch clamp systems are heavily demanded by pharmaceutical companies working with development of ion channel-based drugs.

The newly introduced QPatch HT is the world's first 48-channel gigaseal patch clamp system that can be applied to both voltage-gated and ligand-gated ion channels. With its ability to generate thousands of high-quality data points daily, QPatch HT is enabling new screening paradigms in ion channel drug discovery and safety testing on a truly industrial basis. It is claimed to be taking automated patch clamping to a new and even more powerful level.

"We hope the acquisition of the QPatch technology will assist WuXi PharmaTech in expanding their services into the rapidly increasing fields of cardiac safety testing and ion channel drug discovery," commented Frank Henrichsen, Vice President Sales and Marketing in Sophion Bioscience, the supplier of QPatch HT.

"We are very pleased to have installed the first QPatch HT automated patch clamp system in China, and indeed, the first ever such unit in any integrated drug and medical device R&D outsourcing service company," Dr. Peng Wang, Vice President of Discovery Biology at WuXi PharmaTech, said excitedly, "It will greatly enhan
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Crdentia Announces 2008 First Quarter Results
2. DaVita Renal Dietitians Conduct First-Ever EYE on CKD Workshop
3. Cord Blood America Reports First Quarter Financial Results; Gross Profits Increase
4. The Childrens Hospital of Philadelphia Opens the Worlds First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus
5. Shamir Optical Industry Ltd. to Host Conference Call Announcing First Quarter 2008 Earnings Results
6. First-born babies higher asthma and allergy rates due to pregnancy conditions
7. Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality
8. Population Health Impact Institute to Host First Methods Evaluation Process(TM) (MEP(TM)) Workshop at Annual CMSA Conference
9. AMDL Announces Teleconference and Audio Web Conference to Discuss First Quarter Financial Results
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. BMP Sunstone Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Alternatives, ... permits some patients to quit using drugs while allowing ... Adi Jaffe, the founders of Alternatives, believe that abstinence-only ... before they enter treatment and that this approach hurts ... million people in the United States need treatment for ...
(Date:6/19/2013)... St. Louis, MO (PRWEB) June 19, 2013 ... solutions organization, partnered with ARAMARK Healthcare Technologies to ... equipment management plan with savings of more than ... repair and maintenance service expenditures. , “Driving economies ... the top medical equipment management challenges facing multi-site ...
(Date:6/19/2013)... a world-leading provider of scientific, technical and medical ... of the National Osteoporosis Guideline Group (NOGG) Update ... postmenopausal women and older men in the journal ... Maturitas , the original guidelines have been ... an additional focus on the management of glucocorticoid-induced ...
(Date:6/19/2013)... Mass. (PRWEB) June 19, 2013 ... security solutions, today announced that Imprivata OneSign ® ... KLAS® 2013 Mid-Term Performance Review: Software & Services report ... KLAS laud Imprivata on the superior performance of its ... support, and they indicate that Imprivata is integral to ...
(Date:6/19/2013)... According to Transparency Market Research “Endoscopy devices Market ... Forecast, 2011 – 2017,” the global endoscopy devices market ... and is expected to reach USD 10.8 billion by ... to 2017. Flexible endoscopes formed the largest category in ... for the year 2011. , Related Report : Medical ...
Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3
... NEW YORK, Aug. 7 Duane Reade Holdings, Inc. ... previously announced offers by its wholly-owned subsidiaries, Duane Reade Inc. ... (i) any and all of the Issuers, $210,000,000 outstanding aggregate ... 2010 (the "Floating Rate Notes") (the "FRN Offer") and (ii) ...
... , NEW YORK, Aug. 7 WebMD ... HLTH ) today announced that executives of WebMD are scheduled to ... August 12, 2009 at 1:00 p.m. ET. , , ... to a live audio broadcast of the presentation over the Internet. ...
... The poll results come on the heels of the federal government,s new H1N1 ... A poll conducted by the American Red Cross shows that while a majority ... a third of parents (39%) have received no flu information from their children,s ... http://www.newscom.c o m/cgi-bin/prnh/20090108/RedCrossLOGO ) , , ...
... government to preserve study options , FRIDAY, Aug. 7 (HealthDay ... lines are routinely used by researchers in the United States, says ... known as H1 and H9, accounted for 941 of 1,217 requests, ... stem cell lines housed at the two largest stem cell banks ...
... INDIANAPOLIS Poor communication of the outcomes of medical ... a patient,s hospital discharge is common and can lead ... A new study by researchers from the Regenstrief ... found that hospital discharge summaries are grossly inadequate at ...
... , , WASHINGTON, Aug. 7 "The differences between ... policy experts," say former Chief of Staff to the House Aging Committee ... Americans, lives." , , In an op-ed column in ... Osserman contend, "With no public option, the Senate Finance bill, developed by ...
Cached Medicine News:Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 2Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 3Health News:Red Cross Poll Shows Parents Still Lack H1N1 Information From Schools 2Health News:U.S. Stem Cell Research Seems to Focus on Two Lines 2Health News:Fumbled handoffs can lead to medical errors 2Health News:Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, 'Disappointed' by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bill's 'Prognosis' 2
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... 19, 2013   Life Technologies Corporation ... agreement granting Suzhou Ribo Life Sciences (Ribo) the ... in China using Life,s ... siRNA molecules in combination with Invivofectamine® Rx to ... diseases with high unmet medical need in the ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... Group Inc. (Nasdaq: WWIN ; "Winner Medical" or ... and non-woven fabric made from 100% natural PurCotton® products in ... the 2011 Brean Murray, Carret & Co. Beijing China Growth ... at the JW Marriott Hotel located at 83 Jian Guo ...
... SAN DIEGO, June 22, 2011 OncoSec Medical Incorporated ... ElectroOncology therapies to treat solid tumor cancers, announced today ... to OncoSec,s board of directors and will chair its ... For over 20 years, Dr. Maida has ...
Cached Medicine Technology:Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 2OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 3
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: